Asparaginase Erwinia chrysanthemi
(as-PAYR-uh-jih-NAYS er-WIH-nee-uh krih-SAN-theh-my) This page contains brief information about asparaginase Erwinia chrysanthemi and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Erwinaze |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Asparaginase Erwinia chrysanthemi
Use in CancerAsparaginase Erwinia chrysanthemi is approved to be used with other drugs to treat:
- Acute lymphoblastic leukemia. It is a form of asparaginase made from the bacterium Erwinia chrysanthemi. It is used in patients who can no longer take asparaginase made from E. coli.
Asparaginase Erwinia chrysanthemi is also being studied in the treatment of other types of cancer.
More About Asparaginase Erwinia chrysanthemiDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trials Accepting PatientsFind Clinical Trials for Asparaginase Erwinia Chrysanthemi - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top
